Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 15/20 | 0.66 |
| ▸ | MEN1 | O00255 | 11/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 11/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.66 |
| ▸ | HPGD | P15428 | 2/20 | 0.66 |
| ▸ | LMNA | P02545 | 1/20 | 0.66 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.66 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.66 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.64 |
| ▸ | POLB | P06746 | 2/20 | 0.64 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.64 |
| ▸ | NSD2 | O96028 | 1/20 | 0.64 |
| ▸ | THRB | P10828 | 1/20 | 0.64 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.64 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.64 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.64 |
| ▸ | RECQL | P46063 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12417168 | 0.80 | MAPT (0.82) | MAPTMEN1KMT2AALDH1A1HPGD | |
| SCHEMBL12417177 | 0.79 | MAPT (1.00) | MAPTMEN1KMT2AALDH1A1HPGD | |
| SCHEMBL13856406 | 0.78 | MAPT (1.00) | MAPTMEN1KMT2AALDH1A1HPGD | |
| SCHEMBL7717334 | 0.77 | MAPT (0.56) | MAPTMEN1KMT2AALDH1A1HPGD | |
| SCHEMBL7717337 | 0.77 | MAPT (0.56) | MAPTMEN1KMT2AALDH1A1HPGD | |
| SCHEMBL7717340 | 0.77 | MAPT (0.56) | MAPTMEN1KMT2AALDH1A1HPGD | |
| SCHEMBL16063975 | 0.76 | MAPT (0.75) | MAPTMEN1KMT2AALDH1A1HPGD | |
| SCHEMBL1960867 | 0.74 | MAPT (1.00) | MAPTMEN1KMT2AALDH1A1HPGD | |
| SCHEMBL3762518 | 0.73 | MAPT (0.65) | MAPTMEN1KMT2AALDH1A1HPGD | |
| SCHEMBL3681296 | 0.73 | MAPT (0.65) | MAPTMEN1KMT2AALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220162711-A1 | IDENTIFICATION OF DRUGS TARGETING NON-GENETIC DRUG TOLERANCE PROGRAMS IN CANCER | ETH ZURICH (CH) | 2022-05-26 | — | — | US | claimed |
| EP-3559276-B1 | IDENTIFICATION OF DRUGS TARGETING NON-GENETIC DRUG TOLERANCE PROGRAMS IN CANCER | ETH ZUERICH (CH) | 2022-03-23 | — | — | EP | claimed |
| US-20200325543-A1 | DIAGNOSTIC METHOD | TOLREMO THERAPEUTICS AG (CH) | 2020-10-15 | — | — | US | claimed |
| EP-3714069-A1 | DIAGNOSTIC METHOD | Tolremo Therapeutics AG (CH) | 2020-09-30 | — | — | EP | claimed |
| CN-111417730-A | Diagnostic method | 托雷莫治疗股份公司 | 2020-07-14 | — | — | CN | claimed |
| US-20200087732-A1 | IDENTIFICATION OF DRUGS TARGETING NON-GENETIC DRUG TOLERANCE PROGRAMS IN CANCER | ETH ZURICH (CH) | 2020-03-19 | — | — | US | claimed |
| EP-3559276-A1 | IDENTIFICATION OF DRUGS TARGETING NON-GENETIC DRUG TOLERANCE PROGRAMS IN CANCER | ETH Zurich (CH) | 2019-10-30 | — | — | EP | claimed |
| WO-2018115150-A1 | IDENTIFICATION OF DRUGS TARGETING NON-GENETIC DRUG TOLERANCE PROGRAMS IN CANCER | ETH ZURICH (CH) | 2018-06-28 | — | — | WO | claimed |
| US-12595258-B2 | Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment or amelioration of cancer | TOLREMO THERAPEUTICS AG (CH) | 2026-04-07 | — | — | US | disclosed |
| US-20260076967-A1 | HETEROCYCLIC DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THEIR USE IN THE TREATMENT OR AMELIORATION OF CANCER | TOLREMO THERAPEUTICS AG (CH) | 2026-03-19 | — | — | US | disclosed |
| US-12478624-B2 | Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment or amelioration of cancer | TOLREMO THERAPEUTICS AG (CH) | 2025-11-25 | — | — | US | disclosed |
| US-20250289818-A1 | HETEROCYCLIC DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF CANCER | TOLREMO THERAPEUTICS AG (CH) | 2025-09-18 | — | — | US | disclosed |
| US-20250243191-A1 | HETEROCYCLIC DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THEIR USE IN THE TREATMENT OR AMELIORATION OF CANCER | TOLREMO THERAPEUTICS AG (CH) | 2025-07-31 | — | — | US | disclosed |
| US-20240327394-A1 | HETEROCYCLIC DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THEIR USE IN THE TREATMENT OR AMELIORATION OF CANCER | TOLREMO THERAPEUTICS AG (CH) | 2024-10-03 | — | — | US | disclosed |
| WO-2021064142-A1 | HETEROCYCLIC DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THEIR USE IN THE TREATMENT OR AMELIORATION OF CANCER | TOLREMO THERAPEUTICS AG (CH) | 2021-04-08 | — | — | WO | disclosed |
| US-20200325543-A1 | DIAGNOSTIC METHOD | TOLREMO THERAPEUTICS AG (CH) | 2020-10-15 | — | — | US | disclosed |
| EP-3714069-A1 | DIAGNOSTIC METHOD | Tolremo Therapeutics AG (CH) | 2020-09-30 | — | — | EP | disclosed |
| CN-111417730-A | Diagnostic method | 托雷莫治疗股份公司 | 2020-07-14 | — | — | CN | disclosed |
| WO-2020127200-A1 | HETEROCYCLIC DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF CANCER | TOLREMO THERAPEUTICS AG (CH) | 2020-06-25 | — | — | WO | disclosed |
| US-20200087732-A1 | IDENTIFICATION OF DRUGS TARGETING NON-GENETIC DRUG TOLERANCE PROGRAMS IN CANCER | ETH ZURICH (CH) | 2020-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12595258-B2 | Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment or amelioration of cancer | SLC10A1, MAPT, SLC6A6 | MAPT 2/4885MEN1 547/4885KMT2A 3923/4885 |
| US-20260076967-A1 | HETEROCYCLIC DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THEIR USE IN THE TREATMENT OR AMELIORATION OF CANCER | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, XDH, SLC10A1 | MAPT 425/4885MEN1 1163/4885KMT2A 3925/4885 |
| US-20250289818-A1 | HETEROCYCLIC DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF CANCER | SLC10A1, SLC6A6, SLC10A6 | MAPT 9/4885MEN1 517/4885KMT2A 3610/4885 |
| US-20240327394-A1 | HETEROCYCLIC DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THEIR USE IN THE TREATMENT OR AMELIORATION OF CANCER | TP53, MAPT, SLC10A1 | MAPT 2/4885MEN1 578/4885KMT2A 3119/4885 |
| US-12478624-B2 | Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment or amelioration of cancer | SLC10A1, SLC6A6, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | MAPT 6/4885MEN1 412/4885KMT2A 3445/4885 |
| US-20250243191-A1 | HETEROCYCLIC DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THEIR USE IN THE TREATMENT OR AMELIORATION OF CANCER | TP53, MAPT, SLC10A1 | MAPT 2/4885MEN1 578/4885KMT2A 3119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.